Onvansertib for relapsed small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies onvansertib, a targeted medicine, in people whose small cell lung cancer has come back or did not respond to prior platinum chemotherapy. It aims to shrink tumors and improve outcomes after standard treatment has already been tried.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed small cell lung cancer from pathology (biopsy) or cancer cells from testing
- Your cancer must have at least one measurable tumor spot (it must be large enough to track on scans)
- You have already tried standard platinum chemotherapy and it either failed or you couldn’t tolerate it (and you’ve had no more than two prior chemotherapy lines for widespread disease)
- You’re an adult (18 or older) and you can take oral medicine without trouble
- Your overall health must be good enough for study treatment (ECOG performance status 2 or less) and your blood/organ tests must be within required limits
- You can follow study steps, including signing consent, and women able to get pregnant and men must use effective birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a liposome-encased chemotherapy (irinotecan), a platinum drug, an immunotherapy, and a targeted therapy (anlotinib) as a maintenance treatment for extensive small cell lung cancer. The goal is to see if this approach helps keep the cancer from growing after initial successful treatment.
This study tests a combination of an oral targeted therapy (anlotinib) with a liposomal form of chemotherapy and an immunotherapy drug as maintenance treatment for extensive-stage small cell lung cancer after initial treatment. It aims to keep the cancer from growing again.
This study is testing a new combination of two immunotherapy drugs (adebrelimab and vunakizumab) plus chemotherapy for people with previously untreated extensive-stage small cell lung cancer. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests a new drug, NMS-03305293, in adults with small cell lung cancer that has come back after earlier treatments. The goal is to see if it can help shrink or slow the cancer.
This trial tests a new drug called ABBV-706 against standard treatments (topotecan, lurbinectedin, or amrubicin) for people with small cell lung cancer that has come back or stopped responding to previous therapies. The goal is to see if ABBV-706 works better at controlling the cancer.
This Phase 2 trial tests how well two study drugs (and a combination of them) work in people with extensive-stage small cell lung cancer. It’s mainly for patients whose cancer has come back or who couldn’t tolerate at least some standard treatments, and it aims to see if treatment can shrink tumors and be tolerable.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.